Cargando…

Population pharmacokinetic and pharmacodynamic analyses of safinamide in subjects with Parkinson's disease

Safinamide is an orally administered α‐aminoamide derivative with both dopaminergic and non‐dopaminergic properties. Nonlinear mixed effects models for population pharmacokinetic (PK) and pharmacokinetic–pharmacodynamic (PKPD) analyses were developed using records from, respectively, 623 and 668 pat...

Descripción completa

Detalles Bibliográficos
Autores principales: Loprete, Luca, Leuratti, Chiara, Cattaneo, Carlo, Thapar, Mita M., Farrell, Colm, Sardina, Marco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5045937/
https://www.ncbi.nlm.nih.gov/pubmed/27713822
http://dx.doi.org/10.1002/prp2.251
_version_ 1782457197678034944
author Loprete, Luca
Leuratti, Chiara
Cattaneo, Carlo
Thapar, Mita M.
Farrell, Colm
Sardina, Marco
author_facet Loprete, Luca
Leuratti, Chiara
Cattaneo, Carlo
Thapar, Mita M.
Farrell, Colm
Sardina, Marco
author_sort Loprete, Luca
collection PubMed
description Safinamide is an orally administered α‐aminoamide derivative with both dopaminergic and non‐dopaminergic properties. Nonlinear mixed effects models for population pharmacokinetic (PK) and pharmacokinetic–pharmacodynamic (PKPD) analyses were developed using records from, respectively, 623 and 668 patients belonging to two Phase 3, randomized, placebo‐controlled, double‐blind efficacy studies. The aim was to estimate safinamide population PK parameters in patients with Parkinson's disease (PD) on stable levodopa therapy, and to develop a model of safinamide effect on the PD phase of normal functioning (ON‐time). The final models were internally evaluated using visual predictive checks (VPCs), prediction corrected‐VPC, and nonparametric bootstrap analysis. Safinamide profiles were adequately described by a linear one‐compartmental model with first‐order absorption and elimination. CL/F, Vd/F, and KA (95% confidence interval [CI]) were 4.96 (4.73–5.21) L/h, 166 (158–174) L, and 0.582 (0.335–0.829) h(−1), respectively. CL/F and Vd/F increased with body weight, while age, gender, renal function, and exposure to levodopa did not influence safinamide PK. The observed ON‐time values were adequately described by a linear model, with time in the study period as dependent variable, and rate of ON‐time change and baseline plus offset effect as slope and intercept parameters. Safinamide treatment resulted in an increase in ON‐time of 0.73 h (week 4), with further ON‐time increase with the same slope as placebo. The increase was not influenced by age, levodopa, or safinamide exposure. The population models adequately describe the population PK of safinamide and safinamide effect on ON‐time. No dose adjustments in elderly and mild to moderate renally impaired patients are requested.
format Online
Article
Text
id pubmed-5045937
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-50459372016-10-06 Population pharmacokinetic and pharmacodynamic analyses of safinamide in subjects with Parkinson's disease Loprete, Luca Leuratti, Chiara Cattaneo, Carlo Thapar, Mita M. Farrell, Colm Sardina, Marco Pharmacol Res Perspect Original Articles Safinamide is an orally administered α‐aminoamide derivative with both dopaminergic and non‐dopaminergic properties. Nonlinear mixed effects models for population pharmacokinetic (PK) and pharmacokinetic–pharmacodynamic (PKPD) analyses were developed using records from, respectively, 623 and 668 patients belonging to two Phase 3, randomized, placebo‐controlled, double‐blind efficacy studies. The aim was to estimate safinamide population PK parameters in patients with Parkinson's disease (PD) on stable levodopa therapy, and to develop a model of safinamide effect on the PD phase of normal functioning (ON‐time). The final models were internally evaluated using visual predictive checks (VPCs), prediction corrected‐VPC, and nonparametric bootstrap analysis. Safinamide profiles were adequately described by a linear one‐compartmental model with first‐order absorption and elimination. CL/F, Vd/F, and KA (95% confidence interval [CI]) were 4.96 (4.73–5.21) L/h, 166 (158–174) L, and 0.582 (0.335–0.829) h(−1), respectively. CL/F and Vd/F increased with body weight, while age, gender, renal function, and exposure to levodopa did not influence safinamide PK. The observed ON‐time values were adequately described by a linear model, with time in the study period as dependent variable, and rate of ON‐time change and baseline plus offset effect as slope and intercept parameters. Safinamide treatment resulted in an increase in ON‐time of 0.73 h (week 4), with further ON‐time increase with the same slope as placebo. The increase was not influenced by age, levodopa, or safinamide exposure. The population models adequately describe the population PK of safinamide and safinamide effect on ON‐time. No dose adjustments in elderly and mild to moderate renally impaired patients are requested. John Wiley and Sons Inc. 2016-08-08 /pmc/articles/PMC5045937/ /pubmed/27713822 http://dx.doi.org/10.1002/prp2.251 Text en © 2016 The Authors. Pharmacology Research & Perspectives published by John Wiley & Sons Ltd, British Pharmacological Society and American Society for Pharmacology and Experimental Therapeutics. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs (http://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Articles
Loprete, Luca
Leuratti, Chiara
Cattaneo, Carlo
Thapar, Mita M.
Farrell, Colm
Sardina, Marco
Population pharmacokinetic and pharmacodynamic analyses of safinamide in subjects with Parkinson's disease
title Population pharmacokinetic and pharmacodynamic analyses of safinamide in subjects with Parkinson's disease
title_full Population pharmacokinetic and pharmacodynamic analyses of safinamide in subjects with Parkinson's disease
title_fullStr Population pharmacokinetic and pharmacodynamic analyses of safinamide in subjects with Parkinson's disease
title_full_unstemmed Population pharmacokinetic and pharmacodynamic analyses of safinamide in subjects with Parkinson's disease
title_short Population pharmacokinetic and pharmacodynamic analyses of safinamide in subjects with Parkinson's disease
title_sort population pharmacokinetic and pharmacodynamic analyses of safinamide in subjects with parkinson's disease
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5045937/
https://www.ncbi.nlm.nih.gov/pubmed/27713822
http://dx.doi.org/10.1002/prp2.251
work_keys_str_mv AT lopreteluca populationpharmacokineticandpharmacodynamicanalysesofsafinamideinsubjectswithparkinsonsdisease
AT leurattichiara populationpharmacokineticandpharmacodynamicanalysesofsafinamideinsubjectswithparkinsonsdisease
AT cattaneocarlo populationpharmacokineticandpharmacodynamicanalysesofsafinamideinsubjectswithparkinsonsdisease
AT thaparmitam populationpharmacokineticandpharmacodynamicanalysesofsafinamideinsubjectswithparkinsonsdisease
AT farrellcolm populationpharmacokineticandpharmacodynamicanalysesofsafinamideinsubjectswithparkinsonsdisease
AT sardinamarco populationpharmacokineticandpharmacodynamicanalysesofsafinamideinsubjectswithparkinsonsdisease